Home Cart Sign in  
Chemical Structure| 126-19-2 Chemical Structure| 126-19-2

Structure of Sarsasapogenin
CAS No.: 126-19-2

Chemical Structure| 126-19-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Sarsasapogenin, a natural product isolated and purified from the rhizomes of Anemarrhena asphodeloides Bunge with anti-inflammatory, anti-diabetes,antidepressant, antitumor and protective effects, against glutamate-induced neurotoxicity in the cultured cortical neurons in rats, can improve memory by elevating the low muscarinic acetylcholine receptor density in brains of memory-deficit rat models, and effectively promote the proliferation, differentiation and mineralization of osteoblasts cultured in vitro, also inhibit the generation of osteoclasts from marrow cells.

Synonyms: Parigenin; Sarsagenin; Myogane

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Sarsasapogenin

CAS No. :126-19-2
Formula : C27H44O3
M.W : 416.64
SMILES Code : C[C@@H]1[C@]2(OC[C@@H](C)CC2)O[C@@]3([H])C[C@@]4([H])[C@]5([H])CC[C@]6([H])C[C@@H](O)CC[C@]6(C)[C@@]5([H])CC[C@]4(C)[C@]31[H]
Synonyms :
Parigenin; Sarsagenin; Myogane
MDL No. :MFCD00270414
InChI Key :GMBQZIIUCVWOCD-WWASVFFGSA-N
Pubchem ID :92095

Safety of Sarsasapogenin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Sarsasapogenin

pyroptosis

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
MDCK-MDR1 cells 1.2 µM 120 minutes To investigate the interaction between SSG and P-gp, results showed that transmembrane transport of SSG can be regarded as passive transport. Molecules. 2022 Dec 5;27(23):8556
BV2 cells 0.1–100 µM 24 hours Assess the effect of SA on BV2 cell viability, showing that concentrations of 0.1–100 μM SA had no significant effect on cell viability. Heliyon. 2024 Jan 26;10(3):e25145
Bone marrow-derived macrophages (BMM) 1, 2, 4, 8 µM 48 or 96 hours To assess the cytotoxicity of sarsasapogenin on BMMs, results showed no cytotoxicity at concentrations below 4 μM. Drug Des Devel Ther. 2020 Aug 24;14:3435-3447
Bone marrow-derived macrophages (BMM) 0, 1, 2, 4 µM 6 days To evaluate the effect of sarsasapogenin on RANKL-induced osteoclast formation, results showed significant reduction in TRAP-positive osteoclast area and number. Drug Des Devel Ther. 2020 Aug 24;14:3435-3447
Melan-a cells 1-10 µM 72 hours SAR significantly increased melanin content in melan-a cells and induced melanogenesis by stimulating tyrosinase and MITF protein expression. Biomol Ther (Seoul). 2012 May;20(3):340-5
Huh7 cells 20 µM 9 hours To evaluate the antiviral activity of Sarsasapogenin against CHIKV. Results showed that Sarsasapogenin significantly reduced the production of infectious virus particles, with a 76.4% reduction compared to the EtOH control. Sci Rep. 2020 Apr 14;10(1):6364

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Rats Sprague-Dawley rats Oral 100 mg/kg Single dose To study the pharmacokinetic properties of SAR in rats, showing a relatively long terminal elimination phase half-life (>17 h) Acta Pharmacol Sin. 2010 Aug;31(8):984-9
C57/BL6 male mice LPS-induced calvarial osteolysis model Intragastric administration 5 mg/kg and 10 mg/kg Administered every other day for 7 days To evaluate the protective effect of sarsasapogenin on LPS-induced bone loss, results showed sarsasapogenin significantly inhibited bone loss. Sci Rep. 2021 Jan 22;11(1):2074
C57/BL6 male mice LPS-induced calvarial osteolysis model Intragastric administration 5 mg/kg and 10 mg/kg Administered every other day for 7 days To evaluate the protective effect of sarsasapogenin on LPS-induced bone loss, results showed sarsasapogenin significantly inhibited bone loss. Drug Des Devel Ther. 2020 Aug 24;14:3435-3447
Wistar rats Spinal cord injury model Intragastric administration 5, 10, and 20 mg/kg Once daily until sacrifice Evaluate the effect of SA on motor function recovery in rats with spinal cord injury, showing that 10 and 20 mg/kg SA significantly improved motor function. Heliyon. 2024 Jan 26;10(3):e25145
ICR mice Aβ1-42 intracerebroventricular injection model Oral 6 mg/kg and 30 mg/kg Once daily for 7 days To evaluate the effect of AA13 on learning and memory functions in Aβ1-42-injected mice. Results showed that AA13 significantly improved Aβ1-42-induced learning and memory impairments. CNS Neurosci Ther. 2017 Jun;23(6):498-509

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

12.00mL

2.40mL

1.20mL

24.00mL

4.80mL

2.40mL

Dissolving Methods
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories